Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom.
The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab.
The company was founded in 2003 and is headquartered in Miami, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 30, 24 | -0.08 Decreased by -100.00% | -0.07 Decreased by -14.29% |
| Aug 6, 24 | -0.09 Decreased by -72.41% | -0.06 Decreased by -50.00% |
| Jun 14, 24 | -0.06 Decreased by -100.00% | -0.06 |
| May 1, 24 | -0.06 Decreased by -96.72% | -0.06 |
| Mar 12, 24 | -0.04 Decreased by -100.00% | - |
| Feb 20, 24 | -0.05 Decreased by -147.39% | - |
| Jan 9, 24 | -0.03 Increased by +97.90% | - |
| Nov 7, 23 | -0.03 Increased by +97.87% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Increased by +100.00% | -56.25 M Decreased by -53.84% | - - |
| Jun 30, 24 | 0.00 Increased by +100.00% | -60.38 M Decreased by -65.14% | Decreased by N/A% Decreased by N/A% |
| Apr 30, 24 | N/A Decreased by N/A% | -43.47 M Decreased by -104.41% | - - |
| Mar 31, 24 | 0.00 Decreased by N/A% | -43.47 M Decreased by -104.41% | Decreased by N/A% Decreased by N/A% |
| Jan 31, 24 | -235.00 K Decreased by -200.00% | -36.57 M Decreased by -148.47% | Increased by +15.56 K% Increased by +348.47% |
| Dec 31, 23 | -235.00 K Decreased by -200.00% | -36.57 M Decreased by -148.47% | Increased by +15.56 K% Increased by +348.47% |
| Oct 31, 23 | 0.00 Decreased by N/A% | -21.27 M Increased by +98.65% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -21.27 M Increased by +98.65% | Decreased by N/A% Decreased by N/A% |